Physician profile
Bob B Armin
NPI 1790960888
$5,715.13
in general payments reported to CMS, 2019-2025
10 companies · $43.36 in 2025
The $43.36 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,978 · 2020: $74.09 · 2021: $447 · 2022: $47.15 · 2023: $79.27 · 2024: $45.39 · 2025: $43.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $3,609.52 | 2019-2021 | |
| Stryker Corporation | $1,816.45 | 2019-2023 | Audion Et Dilation System |
| Glaxosmithkline, LLC. | $62.94 | 2022-2025 | Nucala |
| Optinose US, INC. | $48.73 | 2020-2024 | |
| Medical Device Business Services, INC. | $47.96 | 2019 | |
| Genzyme Corporation | $46.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.48 | 2023 | Seglentis |
| Alk-Abello, INC | $21.40 | 2024 | Grastek, Odactra, Ragwitek |
| Neurent Medical Limited | $15.57 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Arbor Pharmaceuticals, INC. | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Armin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.